Kiora Pharmaceuticals, Inc.
KPRX
$2.50
-$0.08-3.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -0.60% | -18.65% | -0.23% | -62.12% | 6.09% |
| Gross Profit | 0.60% | 18.65% | -2.02% | -103.90% | -6.09% |
| SG&A Expenses | 9.88% | 4.55% | -11.97% | 14.89% | 50.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.95% | -6.77% | -7.62% | -26.34% | 25.80% |
| Operating Income | -4.95% | 6.77% | 6.86% | -115.56% | -25.80% |
| Income Before Tax | -232.01% | 81.94% | -1.93% | -115.39% | 0.91% |
| Income Tax Expenses | -131.48% | -- | -- | -- | 2,186.82% |
| Earnings from Continuing Operations | -54.29% | 100.79% | 3.11% | -116.30% | -86.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.29% | 100.79% | 3.11% | -116.30% | -86.17% |
| EBIT | -4.95% | 6.77% | 6.86% | -115.56% | -25.80% |
| EBITDA | -4.78% | 7.09% | 6.75% | -115.55% | -26.00% |
| EPS Basic | -56.07% | 100.77% | -1.30% | -111.14% | 63.10% |
| Normalized Basic EPS | -26.30% | 8.49% | -5.81% | -109.12% | 80.49% |
| EPS Diluted | -56.02% | 100.77% | -1.37% | -115.03% | 63.12% |
| Normalized Diluted EPS | -26.30% | 10.00% | -5.81% | -112.32% | 80.49% |
| Average Basic Shares Outstanding | -1.14% | 1.78% | -4.35% | 46.33% | 404.57% |
| Average Diluted Shares Outstanding | -1.14% | 3.48% | -4.35% | 8.36% | 404.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |